The demand for organ transplants is growing substantially. For example, 28,900 organ transplants were performed in the United States in 2006. During excision and storage, transplant organs can experience oxidative injuries, resulting in the deterioration of the cellular membrane of the organ. Additionally, the process of transplanting an organ results in oxidative stress and cell death. The risks to the patient associated with oxidative injuries are graft rejection, retransplantation, and even mortality. Several approved antioxidant therapies can be used to minimize damage. These therapies generally have unintended side effects or low efficacy. For example, deferoxamine is toxic at high concentrations.

Tego Biosciences is developing an organ storage and preservation solution containing its patented chemicals. The product is intended to reduce oxidative injuries incurred during removal, storage and transplant of an organ. Tego is also exploring whether the same product can be used by stem cell researchers to process and facilitate stem cell development.